The individualized risk prediction test has the potential to improve the efficiency of endoscopic surveillance in BE and to enable early intervention as needed.

TissueCypher better predicts progression in BE than clinicopathologic variables, and can improve on histology as a method to risk stratify patients with BE

Analytical validation study to establish precision, dynamic range, RNA yield, reproducibility, and melanin inhibition

Assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients

Initial development and validation of the 23-GEP establishing a high level of sensitivity and specificity in a broad range of histopathological subtypes

Multicenter study shows clear and significant separation of risk between Class 1 and Class 2 result for DFS,DMFS, MSS, OS using Kaplan-Maier analysis.

To compare American Joint Committee on Cancer (AJCC), International Union Against Cancer (UICC), and Brigham and Women's Hospital (BWH) tumor (T) staging systems for cutaneous squamous cell carcinoma and validate BWH staging against prior data.

The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics.

Despite definitive surgical treatment, a subset of cutaneous squamous cell carcinomas (cSCC) has an increased risk of regional/distant metastasis making it challenging to identify patients most at risk.1 The 40-gene expression profile (40-GEP) prognostic test improves risk stratification for patients with cSCC with known clinical or histologic risk factors, stratifyingpatients’ risk of metastasis as low (Class 1), higher (Class 2A), or highest (Class 2B) risk.

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.